Zobrazeno 1 - 10 of 27 pro vyhledávání: '"Licitra, Lf"'
1
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
Autor: Clement, PM, Gauler, T, Machiels, JP, Haddad, RI, Fayette, J, Licitra, LF, Tahara, M, Cohen, EEW, Cupissol, D, Grau, JJ, Guigay, J, Caponigro, F, de Castro, G, de Souza Viana, L, Keilholz, U, Del Campo, JM, Cong, XJ, Ehrnrooth, E, Vermorken, JB, LUX-H&N 1 investigators
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, vol 27, iss 8
Annals of Oncology, Vol. 27, no.8, p. 1585-1593 (2016)
Annals of Oncology
Annals of oncology
In the LUX-Head & Neck 1 study, older age (≥65 years) did not adversely affect the benefit in patient-reported outcomes and antitumor activity observed with afatinib over methotrexate, which was consistent with findings from the overall population.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c6d12363025e4b33f75070ffc27c42
https://escholarship.org/uc/item/5569t3kk
Zobrazit plný text záznamu
4
Akademický článek
Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111-24111).
Autor: Beyaert SP; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Loriot AE; Group of Computational Biology and Bioinformatics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium., Huyghe ND; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Goebbels RM; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Mendola A; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium., Govaerts AS; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Fortpied C; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium., Baldin P; Department of Pathology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Licitra LF; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; University of Milan, Milan, Italy., Lalami Y; Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Clement PM; Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Machiels JH; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Department of Medical Oncology, Institut Roi Albert II & Cliniques Universitaires Saint-Luc, Brussels, Belgium., Schmitz S; Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Department of Head & Neck Surgery, Institut Roi Albert II & Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Oct 13; Vol. 29 (20), pp. 4076-4087.
Zobrazit plný text záznamu
5
Akademický článek
Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Autor: Secondino S; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.; Department of Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Pedrazzoli P; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.; Department of Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Cellular Therapy & Immunobiology Working Party, European Bone Marrow Transplantation (EBMT), Leiden, Netherlands., Basso S; Pediatric Hematology/Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Cell Factory, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Bossi P; Department of Medical Oncology, University of Brescia-Azienda Socio-Sanitaria Territoriale (ASST) Spedali Civili, Brescia, Italy., Bianco A; Pediatric Hematology/Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Cell Factory, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Imarisio I; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.; Department of Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Pagani A; Department of Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., De Cicco M; Pediatric Hematology/Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Cell Factory, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Muscianisi S; Pediatric Hematology/Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Cell Factory, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Casanova M; Pediatric Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy., Morosi C; Radiology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy., Bergamini C; Head and Neck Medical Oncology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy., Benazzo M; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.; Otolaryngology - Head and Neck Surgery, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Cossu Rocca M; Department of Oncology, European Institute of Oncology (IEO) Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Milan, Italy., Perotti C; Immunohematology and Transfusion Service, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy., Baldanti F; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.; Microbiology and Molecular Virology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Zecca M; Pediatric Hematology/Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy., Licitra LF; Head and Neck Medical Oncology Unit, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Comoli P; Cellular Therapy & Immunobiology Working Party, European Bone Marrow Transplantation (EBMT), Leiden, Netherlands.; Pediatric Hematology/Oncology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.; Cell Factory, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia, Italy.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jul 11; Vol. 14, pp. 1208475. Date of Electronic Publication: 2023 Jul 11 (Print Publication: 2023).
Zobrazit plný text záznamu
6
Akademický článek
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer.
Autor: Noortman WA; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands., Aide N; Nuclear Medicine Department, Centre Hospitalier Universitaire de Caen, 14000 Caen, France., Vriens D; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., Arkes LS; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; Technical Medicine, Delft University of Technology, 2628 CD Delft, The Netherlands., Slump CH; TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands., Boellaard R; Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands., Goeman JJ; Department of Biomedical Data Sciences, Leiden University Medical Center, 2300 RC Leiden, The Netherlands., Deroose CM; Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium., Machiels JP; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium., Licitra LF; Department of Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, 20133 Milan, Italy., Lhommel R; Division of Nuclear Medicine, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, 1200 Brussels, Belgium., Alessi A; Department of Nuclear Medicine-PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy., Woff E; Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), 1070 Bruxelles, Belgium., Goffin K; Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium., Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, 75005 Paris, France., Gal J; Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06100 Nice, France., Temam S; Department of Head and Neck Surgery Gustave Roussy, 94805 Villejuif, France., Delord JP; Department of Medical Oncology, IUCT-Oncopole, 31100 Toulouse, France., van Velden FHP; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands., de Geus-Oei LF; Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.; TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.; Department of Radiation Science & Technology, Delft University of Technology, 2628 CD Delft, The Netherlands.
Publikováno v: Cancers [Cancers (Basel)] 2023 May 09; Vol. 15 (10). Date of Electronic Publication: 2023 May 09.
Zobrazit plný text záznamu
7
Report
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports.
Autor: Colombo E; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gurizzan C; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Ottini A; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Caspani F; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bergamini C; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Locati LD; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Marchiselli C; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Alberti A; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Lorini L; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Licitra LF; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hematology , University of Milan, Milan, Italy., Bossi P; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy.; Department of Oncology and Hematology , University of Brescia, Brescia, Italy., Resteghini C; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v: Frontiers in oncology [Front Oncol] 2023 Feb 28; Vol. 13, pp. 1111146. Date of Electronic Publication: 2023 Feb 28 (Print Publication: 2023).
Zobrazit plný text záznamu
8
Akademický článek
Salivary gland cancers in elderly patients: challenges and therapeutic strategies.
Autor: Colombo E; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Van Lierde C; Otorhinolaryngology-Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven and Department of Oncology, section Head and Neck Oncology, KU Leuven, Leuven, Belgium., Zlate A; Department of Radiation Oncology, Centre Leon Berard, Lyon, France., Jensen A; Department of Radiation Oncology, University Hospitals Giessen and Marburg (UKGM), Marburg, Germany., Gatta G; Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Didonè F; Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Licitra LF; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hematology, University of Milan, Milan, Italy., Grégoire V; Department of Radiation Oncology, Centre Leon Berard, Lyon, France., Vander Poorten V; Otorhinolaryngology-Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven and Department of Oncology, section Head and Neck Oncology, KU Leuven, Leuven, Belgium., Locati LD; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v: Frontiers in oncology [Front Oncol] 2022 Nov 25; Vol. 12, pp. 1032471. Date of Electronic Publication: 2022 Nov 25 (Print Publication: 2022).
Zobrazit plný text záznamu
9
Akademický článek
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Autor: Bourhis J; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Burtness B; Yale School of Medicine & Yale Cancer Center, New Haven, CT 06510, USA., Licitra LF; Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan, Milan, Italy., Nutting C; Royal Marsden NHS Foundation Trust, London, UK., Schoenfeld JD; Brigham & Women's Hospital & Dana-Farber Cancer Institute, Boston, MA 02215, USA., Omar M; Debiopharm International SA, Lausanne, Switzerland., Bouisset F; Debiopharm International SA, Lausanne, Switzerland., Nauwelaerts H; Debiopharm International SA, Lausanne, Switzerland., Urfer Y; Debiopharm International SA, Lausanne, Switzerland., Zanna C; Debiopharm International SA, Lausanne, Switzerland., Cohen EE; University of California, San Diego, La Jolla, CA 92093, USA.
Publikováno v: Future oncology (London, England) [Future Oncol] 2022 May; Vol. 18 (14), pp. 1669-1678. Date of Electronic Publication: 2022 Feb 17.
Zobrazit plný text záznamu
10
Report
Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.
Autor: Lenoci D; Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Carenzo A; Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cavalieri S; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Pistore F; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Serafini MS; Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bossi P; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Schmitz S; Cancer Center, Department of Medical Oncology, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium; Department of Head and Neck Surgery, Cliniques universitaires Saint-Luc, Brussels, Belgium., Machiels JP; Department of Head and Neck Surgery, Cliniques universitaires Saint-Luc, Brussels, Belgium; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium; Institut de Recherche Clinique et Experimentale, Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Licitra LF; Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., De Cecco L; Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: loris.dececco@istitutotumori.mi.it.
Publikováno v: Oral oncology [Oral Oncol] 2022 Mar; Vol. 126, pp. 105756. Date of Electronic Publication: 2022 Feb 02.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje